Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07534592 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07534592 is a Phase 1 study that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT07534592, a Phase 1 study, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
- DRUG Elecoglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2026-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07534592
The ClinicalTrials.gov registry entry for NCT07534592 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.
NCT07534592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07534592 about?
NCT07534592 is a clinical study titled "A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants". The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
What is the current status of trial NCT07534592?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-04-16. Estimated completion is 2026-08-28.
What interventions are being tested in trial NCT07534592?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), Elecoglipron (DRUG).
Who is sponsoring clinical trial NCT07534592?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.